Head-to-head randomized trials are mostly industry sponsored and almost always favor the industry sponsor

Journal of Clinical Epidemiology

Volumn 68, Issue 7, 2015, Pages 811-820

  Flacco, Maria Elena ^a,b   Manzoli, Lamberto ^a,b   Boccia, Stefania ^c   Capasso, Lorenzo ^a   Aleksovska, Katina ^c   Rosso, Annalisa ^d   Scaioli, Giacomo ^e   De Vito, Corrado ^d   Siliquini, Roberta ^e   Villari, Paolo ^d   Ioannidis, John P A ^f  

^a UNIVERSITY OF CHIETI   (Italy)

^b Regional Healthcare Agency of Abruzzo   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e UNIVERSITY OF TURIN   (Italy)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Conflict of interest; Cross sectional study; Head to head comparison; Industry sponsorship; Noninferiority trials; Randomized controlled trials

Indexed keywords

BIOLOGICAL PRODUCT;

COMPARATIVE STUDY; DRUG EFFICACY; DRUG INDUSTRY; DRUG SAFETY; FUNDING; HUMAN; MEDICAL DEVICE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SAMPLE SIZE; ASIA; CONFLICT OF INTEREST; ECONOMICS; EMPIRICAL RESEARCH; EUROPE; FINANCIAL MANAGEMENT; INTERNATIONAL COOPERATION; METHODOLOGY; ORGANIZATION AND MANAGEMENT; PATIENT SELECTION; PROCEDURES; STATISTICS AND NUMERICAL DATA; UNITED STATES;

ASIA; CONFLICT OF INTEREST; DRUG INDUSTRY; EMPIRICAL RESEARCH; EUROPE; INTERNATIONALITY; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RESEARCH SUPPORT AS TOPIC; UNITED STATES;

EID: 84930577263     PISSN: 08954356     EISSN: 18785921     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2014.12.016     Document Type: Review

References (57)

1. J.P. Ioannidis Indirect comparisons: the mesh and mess of clinical trials Lancet 368 2006 1470 1472
2. D.K. Owens, K.N. Lohr, D. Atkins, J.R. Treadwell, J.T. Reston, and E.B. Bass AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions - agency for healthcare research and quality and the effective health-care program J Clin Epidemiol 63 2010 513 523
3. A. Zentner, M. Velasco-Garrido, and R. Busse Methods for the comparative evaluation of pharmaceuticals GMS Health Technol Assess 1 2005 Doc09
4. C. Estellat, and P. Ravaud Lack of head-to-head trials and fair control arms: randomized controlled trials of biologic treatment for rheumatoid arthritis Arch Intern Med 172 2012 237 244
5. P.M. Ridker, and J. Torres Reported outcomes in major cardiovascular clinical trials funded by for-profit and not-for-profit organizations: 2000-2005 JAMA 295 2006 2270 2274
6. L. Bero, F. Oostvogel, P. Bacchetti, and K. Lee Factors associated with findings of published trials of drug-drug comparisons: why some statins appear more efficacious than others PLoS Med 4 2007 e184
7. S. Heres, J. Davis, K. Maino, E. Jetzinger, W. Kissling, and S. Leucht Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics Am J Psychiatry 163 2006 185 194
8. G. Gartlehner, L. Morgan, P. Thieda, and A. Fleg The effect of study sponsorship on a systematically evaluated body of evidence of head-to-head trials was modest: secondary analysis of a systematic review J Clin Epidemiol 63 2010 117 125
9. D.N. Lathyris, N.A. Patsopoulos, G. Salanti, and J.P. Ioannidis Industry sponsorship and selection of comparators in randomized clinical trials Eur J Clin Invest 40 2010 172 182
10. D.L. Sackett, W.M. Rosenberg, J.A. Gray, R.B. Haynes, and W.S. Richardson Evidence based medicine: what it is and what it isn't BMJ 312 1996 71 72
11. E. Stamatakis, R. Weiler, and J.P. Ioannidis Undue industry influences that distort healthcare research, strategy, expenditure and practice: a review Eur J Clin Invest 43 2013 469 475
12. C.D. DeAngelis The influence of money on medical science JAMA 296 2006 996 998
13. N.A. Patsopoulos, J.P. Ioannidis, and A.A. Analatos Origin and funding of the most frequently cited papers in medicine: database analysis BMJ 332 2006 1061 1064
14. H. Melander, J. Ahlqvist-Rastad, G. Meijer, and B. Beermann Evidence b(i)ased medicine - selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications BMJ 326 2003 1171 1173
15. V. Yank, D. Rennie, and L.A. Bero Financial ties and concordance between results and conclusions in meta-analyses: retrospective cohort study BMJ 335 2007 1202 1205
16. J.P. Ioannidis, S. Greenland, M.A. Hlatky, M.J. Khoury, M.R. Macleod, and D. Moher Increasing value and reducing waste in research design, conduct, and analysis Lancet 383 2014 166 175
17. J.S. Ross, K.P. Hill, D.S. Egilman, and H.M. Krumholz Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation JAMA 299 2008 1800 1812
18. K.P. Hill, J.S. Ross, D.S. Egilman, and H.M. Krumholz The ADVANTAGE seeding trial: a review of internal documents Ann Intern Med 149 2008 251 258
19. J. Lexchin, L.A. Bero, B. Djulbegovic, and O. Clark Pharmaceutical industry sponsorship and research outcome and quality: systematic review BMJ 326 2003 1167 1170
20. S. Garattini, and V. Bertele Non-inferiority trials are unethical because they disregard patients' interests Lancet 370 2007 1875 1877
21. J.H. Powers, C.K. Cooper, D. Lin, and D.B. Ross Sample size and the ethics of non-inferiority trials Lancet 366 2005 24 25
22. D.B. Resnik, S. Peddada, and W. Brunson Jr. Research misconduct policies of scientific journals Account Res 16 2009 254 267
23. D.B. Resnik, D. Patrone, and S. Peddada Research misconduct policies of social science journals and impact factor Account Res 17 2010 79 84
24. S. Hopewell, K. Loudon, M.J. Clarke, A.D. Oxman, and K. Dickersin Publication bias in clinical trials due to statistical significance or direction of trial results Cochrane Database Syst Rev 2009 MR000006
25. J.P. Ioannidis Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials JAMA 279 1998 281 286
26. A. Lundh, S. Sismondo, J. Lexchin, O.A. Busuioc, and L. Bero Industry sponsorship and research outcome Cochrane Database Syst Rev 2012 MR000033
27. A.A. Alsheikh-Ali, W. Qureshi, M.H. Al-Mallah, and J.P. Ioannidis Public availability of published research data in high-impact journals PLoS One 6 2011 e24357
28. A.G. Dunn, F.T. Bourgeois, S. Murthy, K.D. Mandl, R.O. Day, and E. Coiera The role and impact of research agendas on the comparative-effectiveness research among antihyperlipidemics Clin Pharmacol Ther 91 2012 685 691
29. A.G. Dunn, K.D. Mandl, E. Coiera, and F.T. Bourgeois The effects of industry sponsorship on comparator selection in trial registrations for neuropsychiatric conditions in children PLoS One 8 2013 e84951
30. L. Manzoli, C. De Vito, G. Salanti, M. D'Addario, P. Villari, and J.P. Ioannidis Meta-analysis of the immunogenicity and tolerability of pandemic influenza A 2009 (H1N1) vaccines PLoS One 6 2011 e24384
31. K. Okike, M.S. Kocher, C.T. Mehlman, and M. Bhandari Industry-sponsored research Injury 39 2008 666 680
32. A. Bhatt Quality of clinical trials: a moving target Perspect Clin Res 2 2011 124 128
33. S. Garattini, and V. Bertele Ethics in clinical research J Hepatol 51 2009 792 797
34. G. Apolone, R. Joppi, V. Bertele, and S. Garattini Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures Br J Cancer 93 2005 504 509
35. FDA Guidance for industry - non-inferiority clinical trials 2010 U.S. Food and Drug Administration Silver Spring, MD, USA
36. P.C. Gotzsche Lessons from and cautions about noninferiority and equivalence randomized trials JAMA 295 2006 1172 1174
37. B. Djulbegovic, and M. Clarke Scientific and ethical issues in equivalence trials JAMA 285 2001 1206 1208
38. C. Chuang-Stein, M. Beltangady, M. Dunne, and B. Morrison The ethics of non-inferiority trials Lancet 371 2008 895 896 author reply 896-7
39. A. Gandjour The ethics of non-inferiority trials Lancet 371 2008 895 author reply 896-7
40. E.Z. Soliman The ethics of non-inferiority trials Lancet 371 2008 895 author reply 896-7
41. B. Djulbegovic, M. Lacevic, A. Cantor, K.K. Fields, C.L. Bennett, and J.R. Adams The uncertainty principle and industry-sponsored research Lancet 356 2000 635 638
42. H. Mann, and B. Djulbegovic Choosing a control intervention for a randomised clinical trial BMC Med Res Methodol 3 2003 7
43. B. Djulbegovic Acknowledgment of uncertainty: a fundamental means to ensure scientific and ethical validity in clinical research Curr Oncol Rep 3 2001 389 395
44. H. Mann, B. Djulbegovic, and P. Gold Failure of equipoise to resolve the ethical tension in a randomized clinical trial J Law Med Ethics 31 2003 5 6
45. B. Djulbegovic The paradox of equipoise: the principle that drives and limits therapeutic discoveries in clinical research Cancer Control 16 2009 342 347
46. C. Gerlinger, and T. Schmelter Determining the non-inferiority margin for patient reported outcomes Pharm Stat 10 2011 410 413
47. J.E. Bekelman, Y. Li, and C.P. Gross Scope and impact of financial conflicts of interest in biomedical research: a systematic review JAMA 289 2003 454 465
48. B. Als-Nielsen, W. Chen, C. Gluud, and L.L. Kjaergard Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? JAMA 290 2003 921 928
49. L. Manzoli, M.E. Flacco, M. D'Addario, L. Capasso, C. De Vito, and C. Marzuillo Non-publication and delayed publication of randomized trials on vaccines: survey BMJ 348 2014 g3058
50. N. Rasmussen, K. Lee, and L. Bero Association of trial registration with the results and conclusions of published trials of new oncology drugs Trials 10 2009 116
51. L.S. Friedman, and E.D. Richter Relationship between conflicts of interest and research results J Gen Intern Med 19 2004 51 56
52. L.L. Kjaergard, and B. Als-Nielsen Association between competing interests and authors' conclusions: epidemiological study of randomised clinical trials published in the BMJ BMJ 325 2002 249
53. R. Jagsi, N. Sheets, A. Jankovic, A.R. Motomura, S. Amarnath, and P.A. Ubel Frequency, nature, effects, and correlates of conflicts of interest in published clinical cancer research Cancer 115 2009 2783 2791
54. S. Krimsky, and L.S. Rothenberg Financial interest and its disclosure in scientific publications JAMA 280 1998 225 226
55. S. Krimsky, and L.S. Rothenberg Conflict of interest policies in science and medical journals: editorial practices and author disclosures Sci Eng Ethics 7 2001 205 218
56. C.G. Smoak Regulatory submissions for medical devices and diagnostics: the basics CDISC J 2011 1 5
57. J.P. Ioannidis Mega-trials for blockbusters JAMA 309 2013 239 240